STAT3 Cancer Research Results

STAT3, Signal transducer and activator of transcription 3: Click to Expand ⟱
Source:
Type: Oncogene
Stat3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, survival, differentiation, and immune response.
Stat3 is frequently found to be constitutively activated in many types of cancers, including breast, prostate, lung, and head and neck cancers. (associated with poor prognosis and reduced survival.)

-STAT3 is typically activated by cytokines (such as IL-6) and growth factors binding to their respective receptors.
-Activated STAT3 upregulates the expression of genes that promote cell cycle progression (e.g., cyclin D1) and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL).
Scientific Papers found: Click to Expand⟱
1153- HNK,    Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,
1119- HNK,    Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis
- vitro+vivo, BC, NA
EMT↓, MSCmark↓, EM↑, STAT3↓, Zeb1↓, E-cadherin↑,
2883- HNK,    Honokiol targets mitochondria to halt cancer progression and metastasis
- Review, Var, NA
ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoPv↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
2895- HNK,    Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity
- in-vitro, Lung, PC9
eff↑, TumCP↓, mt-ROS↑, Prx3↑, mt-STAT3↓, *toxicity∅, selectivity↑, ChemoSen↑,
2897- HNK,    Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, PC9 - in-vitro, Lung, A549
TumCP↓, Apoptosis↑, EGFR↓, PI3K↓, Akt↓, STAT3↓, TumCI↓, TNF-α↑, NF-kB↓, VEGF↓, MMP9↓, COX2↓,
4639- HT,    Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
TumCP↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, p27↑, Apoptosis↑, Casp↑, cl‑PARP↑, Bax:Bcl2↑, p‑Akt↓, p‑STAT3↓, NF-kB↓, AR↓, ROS↑, *BioAv↓, *toxicity∅,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
1277- I3C,  GEN,    Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein
- in-vitro, PC, PANC1
STAT3↓, Apoptosis↑,
1070- IVM,    Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation
- vitro+vivo, GBM, NA
TumCG↓, LC3II↑, p62↓, ATP↓, Pyruv↓, GlucoseCon↑, HK2↓, PFK1↓, GLUT4↓, Glycolysis↓, JAK2↓, p‑STAT3↓, p‑STAT5↓,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,
2351- lamb,    Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
proCasp3↓, proPARP↓, LDHA↓, Glycolysis↓, HK2↓, PKM2↓, lactateProd↓, p‑STAT3↓, cycD1/CCND1↓, cMyc↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, ROS↑, eff↓,
1025- LT,  Api,    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
- in-vivo, Lung, NA
TumCG↓, Apoptosis↑, PD-L1↓, p‑STAT3↓,
2925- LT,    Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3
- in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MCF-7
HSP90↓, p‑STAT3↓, Apoptosis↑, selectivity↑,
2924- LT,    Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1
- in-vitro, GC, NA - in-vivo, NA, NA
p‑STAT3↓, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, HSP90↓,
2921- LT,    Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies
- Review, Nor, NA
*hepatoP↑, *AMPK↑, *SIRT1↑, *ROS↓, STAT3↓, TNF-α↓, NF-kB↓, *IL2↓, *IFN-γ↓, *GSH↑, *SREBP1↓, *ZO-1↑, *TLR4↓, BAX↑, Bcl-2↓, XIAP↓, Fas↑, Casp8↑, Beclin-1↑, *TXNIP↓, *Casp1↓, *IL1β↓, *IL18↓, *NLRP3↓, *MDA↓, *SOD↑, *NRF2↑, *ER Stress↓, *ALAT↓, *AST↓, *iNOS↓, *IL6↓, *HO-1↑, *NQO1↑, *PPARα↑, *ATF4↓, *CHOP↓, *Inflam↓, *antiOx↑, *GutMicro↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
3268- Lyco,    Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders
- Review, AD, NA
*BioAv↓, *AntiCan↑, *ROCK1↓, *Ki-67↓, *ICAM-1↓, *cardioP↑, *antiOx↑, *NQO1↑, *HO-1↑, *TNF-α↓, *IL22↓, *NRF2↑, *NF-kB↓, *MDA↓, *Catalase↑, *SOD↑, *GSH↑, *cognitive↑, *tau↓, *hepatoP↑, *MMP2↑, *AST↓, *ALAT↓, *P450↑, *DNAdam↓, *ROS↓, *neuroP↑, *memory↑, *Ca+2↓, *Dose↝, *Dose↑, *Dose↝, *toxicity∅, PGE2↓, CDK2↓, CDK4↓, STAT3↓, NOX↓, NOX4↓, ROS↓, *SREBP1↓, *FASN↓, *ACC↓,
3264- Lyco,    Pharmacological potentials of lycopene against aging and aging‐related disorders: A review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
*antiOx↑, *ROS↓, *SOD↑, *Catalase↑, *GSH↑, *GSTs↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *iNOS↓, *NO↓, *TAC↑, *NOX4↓, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *IL1β↓, *TNF-α↓, *TLR2↓, *TLR4↓, *VCAM-1↓, *ICAM-1↓, *STAT3↓, *NF-kB↓, *ERK↓, *BP↓, ROS↓, PGE2↓, cardioP↑, *neuroP↑, *creat↓, *RenoP↑, *CRM↑,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,
4795- Lyco,    Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer
- Review, BC, NA
TumCG↓, TumCCA↑, Apoptosis↑, P53↝, BAX↝, cycD1/CCND1↓, ERK↓, Akt↓, STAT3↓, NRF2↝, NF-kB↓, ITGB1↓, ITGA5↓, FAK↓, MMP9↓, EMT↓,
4793- Lyco,    Lycopene treatment inhibits activation of Jak1/Stat3 and Wnt/β-catenin signaling and attenuates hyperproliferation in gastric epithelial cells
- in-vitro, GC, AGS
antiOx↑, AntiCan↑, ROS↓, JAK1↓, STAT3↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, cycE/CCNE↓, TumCP↓, Risk↓,
1197- MAG,    Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells
- in-vivo, MS, NA
Weight↑, Th17↓, STAT3↓,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2379- MET,    Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer
- in-vitro, Bladder, T24/HTB-9 - in-vitro, BC, UMUC3
PKM2↓, p‑STAT3↓, TumCG↓, eff↑, chemoP↑, AMPK↑,
3483- MF,    Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway
- NA, Stroke, NA
*Inflam↓, *STAT3↓, *p‑STAT3↓,
533- MF,    Effects of extremely low-frequency magnetic fields on human MDA-MB-231 breast cancer cells: proteomic characterization
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCD↑, necrosis↑, mt-ROS↑, other↑, *STAT3↓, STAT3↑,
1203- MSM,    Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways
- vitro+vivo, BC, MDA-MB-231
tumCV↓, STAT3↓, STAT5↓, IGF-1↓, Hif1a↓, VEGF↓, Brk/PTK6↓, IGF-1R↓,
1170- MushCha,    Chaga mushroom extract suppresses oral cancer cell growth via inhibition of energy metabolism
- in-vitro, Oral, HSC4
tumCV↓, TumCP↓, TumCCA↑, STAT3↓, Glycolysis↓, MMP↓, TumAuto↑, p38↑, NF-kB↑,
930- MushShi,    Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation
- in-vitro, Ovarian, NA
p‑STAT3↓, PTPN6↑, cycD1/CCND1↓, Bcl-2↓, Mcl-1↓, survivin↓, VEGF↓,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
1269- NCL,    Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway
- in-vitro, Pca, DU145
STAT3↓, TumCG↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, cMyc↓, Bcl-xL↓,
1271- NCL,    Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
- vitro+vivo, Ovarian, SKOV3
Wnt/(β-catenin)↓, mTOR↓, STAT3↓, NF-kB↓, NOTCH↓, TumCG↓, Apoptosis↑, MEK↓, ERK↓, mitResp↓, Glycolysis↓, ROS↑, JNK↑,
5253- NCL,    Niclosamide: Beyond an antihelminthic drug
- Review, Var, NA
TumCP↓, Apoptosis↑, EMT↓, β-catenin/ZEB1↓, TumCG↓, toxicity↓, Wnt↓, LRP6↓, eff↑, DR5↑, mTORC1↓, pH↓, CSCs↓, IL6↓, JAK1↓, STAT3↓, ChemoSen↑, TumCG↓, tumCV↓, NOTCH↓, NF-kB↓, EGFR↓, ROS↑, RadioS↑, cFos↓, cJun↓, E2Fs↓, cMyc↓, Half-Life↓, BioAv↝,
5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, RAS↓, STAT3↓, NOTCH↓, E2Fs↓, mTOR↓, eff↑, PD-1↓, PD-L1↓, BioAv↝, toxicity↓, BioAv↑, ETC↑, NADH:NAD↓, TCA↑, Warburg↓, Diff↑, AMPK↑, P53↑, PP2A↑, HIF-1↓, KRAS↓, Myc↓, RadioS↑, ChemoSen↑, Dose↝, Dose↑,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
4649- OLEC,    Anticancer molecular mechanisms of oleocanthal
Apoptosis↑, HGF/c-Met↝, STAT3↝,
4646- OLEC,    Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology
- Review, Var, NA
BioAv↓, *Inflam↓, *antiOx↓, cMET↓, STAT3↓, TNF-α↓, COX2↓, EMT↓, angioG↓, *GutMicro↝, eff↑,
4647- OLEC,    Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer
- Review, Var, NA
*Inflam↓, AntiCan↑, *COX2↓, *ROS↓, *TNF-α↓, *IL1β↓, *iNOS↓, TumCP↓, *AntiAg↑, mTOR↓, STAT3↓, ERK↓, p‑Akt↓, Bcl-2↓, ROS↑, PSA↓,
1227- OLST,    Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling
- in-vivo, CRC, NA
OS↑, Inflam↓, TumCG↓, STAT3↓, NF-kB↓, β-catenin/ZEB1↓, Slug↓, XIAP↓, CDK4↓, cycD1/CCND1↓, Bcl-2↓,
1672- PBG,    The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers
- Review, BC, NA
ChemoSen↓, RadioS↑, Inflam↓, AntiCan↑, Dose∅, mtDam↑, Apoptosis?, OCR↓, ATP↓, ROS↑, ROS↑, LDH↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eNOS↑, iNOS↑, eff↑, hTERT/TERT↓, cycD1/CCND1↓, eff↑, eff↑, eff↑, eff↑, STAT3↓, TIMP1↓, IL4↓, IL10↓, OS↑, Dose∅, ER Stress↑, ROS↑, NF-kB↓, p65↓, MMP↓, TumAuto↑, LC3II↑, p62↓, TLR4↓, mtDam↑, LDH↓, ROS↑, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDH↓, IL10↓, HDAC8↓, eff↑, eff↑, P21↑,
4918- PEITC,    Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights
- Review, Var, NA
Apoptosis↑, TumCP↓, angioG↓, TumMeta↓, NF-kB↓, Akt↓, MAPK↓, *BioAv↓, ROS↑, lipid-P↑, AIF↑, Cyt‑c↑, DR4↑, DR5↑, TumCCA↑, JAK↓, STAT3↓, MMP2↓, MMP9↓, PKCδ↓, Hif1a↓, JNK↓, Mcl-1↓, COX2↓, MMP↓, Casp3↑, ChemoSen↑, *BioAv↓, Half-Life↓,
4936- PEITC,    PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth
- in-vivo, BC, MDA-MB-231
TumCG↓, CD34↓, CD11b↓, CSCs↓, ALC∅, CD4+↓, NF-kB↓, STAT3↓, Hif1a↓,
5186- PEITC,    Phenethyl Isothiocyanate inhibits STAT3 activation in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
TumCP↓, TumCCA↑, STAT3↓, p‑JAK2↓, eff↓, TumCCA↑, AR↓, ROS↑,
1165- PI,    Piperine inhibits IL-1β-induced IL-6 expression by suppressing p38 MAPK and STAT3 activation in gastric cancer cells
- in-vitro, GC, TMK-1
p38↓, IL6↓, STAT3↓,

Showing Research Papers: 151 to 200 of 276
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 276

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↓, 3,   Catalase↑, 2,   CYP1A1↓, 1,   CYP1A1↑, 1,   GPx↓, 1,   GPx↑, 4,   GSH↓, 2,   GSH↑, 2,   GSR↓, 1,   GSR↑, 1,   GSTA1↑, 1,   GSTs↓, 1,   HO-1↓, 1,   HO-1↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 1,   NOX4↓, 1,   NOX4↑, 1,   NQO1↓, 1,   NRF2↓, 2,   NRF2↑, 2,   NRF2↝, 1,   Prx3↑, 1,   ROS↓, 5,   ROS↑, 18,   mt-ROS↑, 3,   SIRT3↓, 1,   SIRT3↑, 1,   SOD↓, 2,   SOD↑, 2,   SOD2↓, 2,   Trx1↑, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 2,   CDC2↓, 1,   ETC↑, 1,   MEK↓, 1,   mitResp↓, 2,   MMP↓, 7,   MPT↑, 1,   mtDam↑, 2,   OCR↓, 2,   e-Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 3,   ATG7↑, 1,   CAIX↑, 1,   cMyc↓, 6,   FASN↓, 1,   GLO-I↓, 1,   GlucoseCon↑, 1,   Glycolysis↓, 5,   HK2↓, 3,   lactateProd↓, 1,   LDH↓, 3,   LDHA↓, 1,   NADH:NAD↓, 1,   PFK↓, 1,   PFK1↓, 1,   PKM2↓, 4,   PPARγ↑, 3,   Pyruv↓, 1,   SIRT1↓, 1,   SIRT1↑, 1,   TCA↑, 1,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 11,   p‑Akt↓, 5,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 18,   BAD↑, 1,   Bak↑, 1,   BAX↓, 2,   BAX↑, 7,   BAX↝, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 12,   Bcl-2↑, 1,   Bcl-xL↓, 2,   Casp↑, 2,   Casp1↓, 1,   Casp3↓, 1,   Casp3↑, 12,   proCasp3↓, 1,   Casp8↑, 3,   Casp9↑, 6,   cl‑Casp9↑, 1,   proCasp9↓, 1,   cFLIP↓, 1,   Chk2↓, 1,   Cyt‑c↑, 6,   DR4↑, 1,   DR5↑, 5,   Fas↑, 3,   FasL↑, 1,   HGF/c-Met↓, 1,   HGF/c-Met↝, 1,   hTERT/TERT↓, 2,   iNOS↑, 1,   JNK↓, 1,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 3,   MAPK↑, 3,   Mcl-1↓, 5,   Mcl-1↑, 1,   MDM2↓, 1,   p‑MDM2↓, 1,   Myc↓, 1,   necrosis↑, 1,   p27↑, 4,   p38↓, 2,   p38↑, 1,   p‑p38↑, 1,   survivin↓, 5,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,   EF-1α↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   cJun↑, 1,   H3↓, 1,   H3↑, 1,   H4↓, 1,   H4↑, 1,   HATs↑, 1,   other↑, 1,   tumCV↓, 6,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   cl‑CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 5,   GRP78/BiP↑, 2,   HSP90↓, 2,   p‑PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   BNIP3↑, 1,   LC3II↑, 4,   p62↓, 2,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   DNAdam↓, 1,   DNAdam↑, 1,   DNArepair↑, 1,   P53↓, 1,   P53↑, 6,   P53↝, 1,   PARP↑, 2,   cl‑PARP↑, 4,   proPARP↓, 1,   PCNA↓, 4,   TP53↓, 1,   γH2AX↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 6,   CDK4↓, 7,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 10,   cycE/CCNE↓, 3,   E2Fs↓, 2,   P21?, 1,   P21↓, 1,   P21↑, 6,   p‑RB1↓, 1,   TumCCA↑, 12,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 3,   CD34↓, 2,   CD44↓, 1,   cFos↓, 1,   cFos↑, 1,   cMET↓, 1,   p‑cMET↑, 1,   CSCs↓, 4,   CSCsMark↓, 1,   Diff↑, 1,   EMT↓, 11,   ERK↓, 7,   p‑ERK↓, 1,   FOXO3↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 3,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC8↓, 1,   IGF-1↓, 2,   IGF-1R↓, 2,   LRP6↓, 1,   MSCmark↓, 1,   mTOR↓, 11,   p‑mTOR↓, 1,   mTORC1↓, 2,   Nanog↓, 1,   Nestin↓, 3,   NOTCH↓, 4,   NOTCH1↓, 2,   NOTCH3↓, 1,   OCT4↓, 1,   PI3K↓, 6,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 2,   PTPN6↑, 1,   RAS↓, 4,   RAS↑, 1,   Shh↓, 1,   SOX2↓, 1,   p‑Src↓, 1,   STAT3↓, 35,   STAT3↑, 1,   STAT3↝, 1,   p‑STAT3↓, 12,   mt-STAT3↓, 1,   STAT5↓, 1,   p‑STAT5↓, 1,   p‑STAT6↓, 1,   TumCG↓, 11,   TumCG↑, 1,   Wnt↓, 7,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AntiAg↑, 1,   AXL↓, 1,   Brk/PTK6↓, 1,   Ca+2↑, 1,   CD11b↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 6,   EM↑, 1,   FAK↓, 3,   ITGA5↓, 1,   ITGB1↓, 2,   KRAS↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP13↓, 1,   MMP2↓, 8,   MMP7↓, 1,   MMP9↓, 9,   MMPs↓, 3,   N-cadherin↓, 4,   PKCδ↓, 1,   Rac1↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 5,   SOX4↓, 1,   TIMP1↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   Treg lymp↓, 1,   TumCI↓, 7,   TumCMig↓, 4,   TumCP↓, 14,   TumMeta↓, 4,   TumMeta↑, 2,   Twist↓, 3,   Tyro3↓, 1,   VCAM-1↓, 1,   Vim↓, 3,   Vim↑, 1,   Zeb1↓, 2,   ZO-1↑, 1,   β-catenin/ZEB1↓, 9,   β-catenin/ZEB1↑, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   EGFR↓, 6,   EGFR↑, 1,   p‑EGFR↓, 1,   eNOS↑, 1,   HIF-1↓, 1,   Hif1a↓, 9,   NO↓, 1,   NO↝, 1,   VEGF↓, 12,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

BBB↓, 1,   BBB↑, 1,   GLUT1↑, 1,   GLUT3↑, 1,   GLUT4↓, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   CD4+↓, 1,   CD4+↑, 1,   COX2↓, 10,   CXCR4↓, 1,   FOXP3↓, 1,   ICAM-1↓, 1,   IKKα↓, 2,   IL1↓, 1,   IL1↑, 1,   IL10↓, 2,   IL10↑, 1,   IL1β↓, 1,   IL2↑, 2,   IL4↓, 1,   IL4↑, 2,   IL6↓, 8,   IL8↓, 1,   Inflam↓, 3,   JAK↓, 1,   JAK1↓, 4,   JAK2↓, 2,   p‑JAK2↓, 1,   NF-kB↓, 20,   NF-kB↑, 1,   NK cell↑, 1,   p65↓, 4,   p‑p65↓, 1,   PD-1↓, 2,   PD-L1↓, 2,   PGE2↓, 7,   PSA↓, 1,   PSA∅, 1,   T-Cell↑, 1,   Th1 response↑, 1,   Th17↓, 1,   TLR4↓, 1,   TNF-α↓, 7,   TNF-α↑, 3,  

Cellular Microenvironment ⓘ

NOX↓, 1,   pH↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,   PP2A↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   GR↑, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 7,   BioAv↑, 3,   BioAv↝, 4,   ChemoSen↓, 1,   ChemoSen↑, 12,   Dose↑, 1,   Dose↝, 3,   Dose∅, 3,   eff↓, 2,   eff↑, 15,   Half-Life↓, 3,   Half-Life↝, 4,   RadioS↑, 8,   selectivity↑, 6,  

Clinical Biomarkers ⓘ

ALC∅, 1,   AR↓, 3,   BMPs↑, 1,   CEA↓, 1,   EGFR↓, 6,   EGFR↑, 1,   p‑EGFR↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 2,   IL6↓, 8,   KRAS↓, 1,   LDH↓, 3,   Myc↓, 1,   NSE↓, 1,   PD-L1↓, 2,   PSA↓, 1,   PSA∅, 1,   TP53↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 6,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 5,   chemoPv↑, 1,   ChemoSideEff↓, 1,   OS↑, 5,   QoL↑, 1,   radioP↑, 1,   Risk↓, 1,   toxicity↓, 3,   Weight↑, 1,  
Total Targets: 382

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 6,   Catalase↑, 7,   GPx↑, 2,   GSH↑, 7,   GSR↑, 1,   GSTs↑, 3,   HO-1↑, 4,   lipid-P↓, 3,   MDA↓, 4,   NOX4↓, 1,   NQO1↑, 2,   NRF2↑, 6,   ROS↓, 10,   SOD↑, 7,   TAC↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   ALAT↓, 3,   AMPK↑, 1,   CRM↑, 1,   FASN↓, 1,   NADPH↓, 1,   PPARα↑, 1,   SIRT1↑, 1,   SREBP1↓, 2,  

Cell Death ⓘ

Casp1↓, 1,   Casp3↓, 2,   iNOS↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↓, 1,   ER Stress↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,  

Migration ⓘ

AntiAg↑, 1,   Ca+2↓, 1,   Ki-67↓, 1,   MMP2↑, 1,   p‑Rac1↓, 1,   ROCK1↓, 1,   TXNIP↓, 1,   VCAM-1↓, 1,   ZO-1↑, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↓, 1,   NO↓, 2,  

Barriers & Transport ⓘ

BBB↑, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   ICAM-1↓, 2,   IFN-γ↓, 1,   IKKα↑, 1,   IL1↓, 1,   IL10↓, 1,   IL10↑, 1,   IL18↓, 1,   IL1β↓, 4,   IL2↓, 1,   IL22↓, 1,   IL6↓, 3,   IL8↓, 1,   Inflam↓, 8,   NF-kB↓, 3,   PGE2↓, 1,   TLR2↓, 1,   TLR4↓, 2,   TNF-α↓, 5,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   Dose↑, 1,   Dose↝, 2,   eff↑, 1,   Half-Life↝, 1,   P450↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 3,   ALP↓, 1,   AST↓, 3,   BP↓, 1,   creat↓, 1,   GutMicro↑, 1,   GutMicro↝, 1,   IL6↓, 3,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 2,   chemoP↑, 1,   cognitive↑, 1,   hepatoP↑, 3,   memory↑, 1,   neuroP↑, 5,   RenoP↑, 2,   toxicity∅, 3,  
Total Targets: 95

Scientific Paper Hit Count for: STAT3, Signal transducer and activator of transcription 3
21 Curcumin
15 Thymoquinone
13 Quercetin
12 Apigenin (mainly Parsley)
10 Resveratrol
9 Baicalein
9 Capsaicin
8 Ashwagandha(Withaferin A)
8 EGCG (Epigallocatechin Gallate)
8 Betulinic acid
8 Honokiol
8 Silymarin (Milk Thistle) silibinin
7 Chrysin
6 Berberine
6 brusatol
6 Luteolin
6 Lycopene
5 Artemisinin
5 Caffeic acid
5 Garcinol
5 Pterostilbene
4 Berbamine
4 Sorafenib (brand name Nexavar)
4 Carnosic acid
4 Celastrol
4 Ellagic acid
4 Niclosamide (Niclocide)
4 Piperine
4 Piperlongumine
3 Cisplatin
3 Radiotherapy/Radiation
3 Chemotherapy
3 Boswellia (frankincense)
3 Propolis -bee glue
3 Magnetic Fields
3 Fisetin
3 Sulforaphane (mainly Broccoli)
3 HydroxyTyrosol
3 Oleocanthal
3 Phenethyl isothiocyanate
3 Rosmarinic acid
3 Shikonin
3 Ursolic acid
2 Andrographis
2 Ascorbyl Palmitate
2 Melatonin
2 Arctigenin
2 Baicalin
2 Brucea javanica
2 borneol
2 Boron
2 Emodin
2 Gambogic Acid
2 Genistein (soy isoflavone)
2 Ivermectin
2 Metformin
2 Vitamin C (Ascorbic Acid)
2 Sanguinarine
2 Vitamin K2
1 Allicin (mainly Garlic)
1 Alpha-Lipoic-Acid
1 Gemcitabine (Gemzar)
1 Astaxanthin
1 Biochanin A
1 Atorvastatin
1 Bufalin/Huachansu
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Carvacrol
1 Cinnamon
1 Oxygen, Hyperbaric
1 methylseleninic acid
1 Deguelin
1 Ferulic acid
1 Gallic acid
1 immunotherapy
1 Paclitaxel
1 Ginkgo biloba
1 Indole-3-carbinol
1 lambertianic acid
1 Magnolol
1 Methylsulfonylmethane
1 Mushroom Chaga
1 Mushroom Shiitake, AHCC
1 Naringin
1 Oleuropein
1 Orlistat
1 Plumbagin
1 VitK3,menadione
1 Parthenolide
1 salinomycin
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:373  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page